Novo Nordisk A/S’s obesity pill will allow it to tap into a massive population of patients that have not yet taken GLP-1s, ...

Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the ...

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Novo Nordisk’s Wegovy (semaglutide injection) has received a new approval from the Medicines and Healthcare products ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

New research calls for routine risk stratification of MASLD in people with obesity to detect and manage liver disease earlier ...

Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...

CenterWell Pharmacy announced that it will dispense Eli Lilly's obesity drugs within employer weight management programs. | ...

Laboratories are no longer peripheral. They are central to modern clinical development - enabling earlier decision-making, ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is ...

A low-carbohydrate diet combined with resistance training achieves notable weight loss even in individuals with a high ...